Frontline Management of Atopic Dermatitis in Adults - Episode 14
JADE COMPARE: Considerations for Comparisons Among Systemic Agents in Atopic Dermatitis
Panelists discuss how the JADE COMPARE study (Bieber 2021) found similar EASI-75 response rates at 16 weeks for abrocitinib (71.0% at 200 mg, 60.3% at 100 mg) and dupilumab (65.5%). Abrocitinib had more nausea/acne; dupilumab had more conjunctivitis. Adverse effect (AE) withdrawal rates were low.
Video content above in prompted by the following:
- Discuss the JADE COMPARE study, where abrocitinib was compared to a placebo and dupilumab (Bieber 2021). When would you recommend a Janus kinase inhibitor over a biologic?
- 71.0% of the 221 patients taking 200 mg abrocitinib and 60.3% of the 229 patients taking 100 mg abrocitinib achieved EASI-75 response at week 16.
- 65.5% of the 232 patients taking dupilumab achieved EASI-75 response at week 16.
- There was no significant difference in EASI-75 response between patients taking abrocitinib (with either dose) and those taking dupilumab.
- Nausea and acne were more common in the abrocitinib patients than in the dupilumab patients; conjunctivitis was more common in the dupilumab patients.
- 4.4% of patients taking 200 mg abrocitinib, 2.5% of patients taking 100 mg abrocitinib, and 3.3% of patients taking dupilumab withdrew due to an AE.
